Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-04-19

Clinical Trial Update: S 48168 (ARM 210) for the Treatment of RYR1-related Myopathies (RYR1-RM) [Phase 1]

View source ↗

Summary

Phase 1 trial of S 48168 (ARM 210) for RYR1-related myopathy has completed enrollment and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • S 48168 (ARM 210)

Snippet

Sponsor: RyCarma Therapeutics, Inc. | Conditions: RYR-1 Myopathy | Phase 1 | Status: COMPLETED | Results posted: 2024-04-19